Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease

Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease Letters 1. Howard R, Zubko O, Bradley R, et al; Minocycline in Alzheimer Disease efits (as assessed by changes in scores of the Mini-Mental State Efficacy (MADE) Trialist Group. Minocycline at 2 different dosages vs placebo Examination and the Bristol Activities of Daily Living scale) in for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. a cohort of persons with a diagnosis of early AD. The rationale 2019;77(2):164-174. doi:10.1001/jamaneurol.2019.3762 for the investigation of minocycline stems from preclinical evi- 2. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed dence supporting the notion that the drug targets critical de- minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006;7:56. doi:10.1186/1471-2202-7-56 terminants of AD-like β-amyloid, hyperphosphorylated tau, 3. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. and microglia activation and neuroinflammation. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine Disappointingly, but possibly not surprisingly, the drug enlargement and long-term potentiation coordinately. Proc Natl Acad SciUSA. failed to prove beneficial effects. However, we believe that valu- 2008;105(49):19520-19525. doi:10.1073/pnas.0807248105 able information can be still inferred from the study. The 4. Hwang JJ, Park M-H, Choi S-Y, Koh J-Y. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease

LeWitt, Peter A.
JAMA Neurology , Volume 77 (8) – Aug 29, 2020
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/dopamine-metabolite-biomarkers-and-testing-for-disease-modification-in-MzryLhAkKR

References (7)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2020.1928
Publisher site
See Article on Publisher Site

Abstract

Letters 1. Howard R, Zubko O, Bradley R, et al; Minocycline in Alzheimer Disease efits (as assessed by changes in scores of the Mini-Mental State Efficacy (MADE) Trialist Group. Minocycline at 2 different dosages vs placebo Examination and the Bristol Activities of Daily Living scale) in for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. a cohort of persons with a diagnosis of early AD. The rationale 2019;77(2):164-174. doi:10.1001/jamaneurol.2019.3762 for the investigation of minocycline stems from preclinical evi- 2. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed dence supporting the notion that the drug targets critical de- minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006;7:56. doi:10.1186/1471-2202-7-56 terminants of AD-like β-amyloid, hyperphosphorylated tau, 3. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. and microglia activation and neuroinflammation. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine Disappointingly, but possibly not surprisingly, the drug enlargement and long-term potentiation coordinately. Proc Natl Acad SciUSA. failed to prove beneficial effects. However, we believe that valu- 2008;105(49):19520-19525. doi:10.1073/pnas.0807248105 able information can be still inferred from the study. The 4. Hwang JJ, Park M-H, Choi S-Y, Koh J-Y.

Journal

JAMA Neurology – American Medical Association

Published: Aug 29, 2020

There are no references for this article.